Aelis Farma : The phase IIb study for AEF0117 failed to reach its primary endpoint
>AEF0117 failed to reach its primary endpoint for phase IIb - We learned this morning of the phase II results for the group’s flagship trial evaluating AEF0117 in patients (n=330) seeking treatment for cannabis use disorder (CUD). The main aim of this study was to show that AEF0117 results in a larger proportion of ‘responders’ (patients with cannabis consumption = 1 day per week) compared to a placebo for patients seeking treatment for moderate to severe CUD, accordi...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.